KR20140051846A - 칼슘 감지 수용체 조절자로서의 벤조[ｂ][1,4]옥사진 유도체 - Google Patents

칼슘 감지 수용체 조절자로서의 벤조[ｂ][1,4]옥사진 유도체 Download PDF

Info

Publication number
KR20140051846A
KR20140051846A KR1020137026964A KR20137026964A KR20140051846A KR 20140051846 A KR20140051846 A KR 20140051846A KR 1020137026964 A KR1020137026964 A KR 1020137026964A KR 20137026964 A KR20137026964 A KR 20137026964A KR 20140051846 A KR20140051846 A KR 20140051846A
Authority
KR
South Korea
Prior art keywords
benzo
substituted
oxazine
ethyl
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137026964A
Other languages
English (en)
Korean (ko)
Inventor
마노지쿠마르 람프라사드 슈크라
사르데 강아람 안쿠쉬
파취푸테 디립 비풀
마지드 바쉬르 세이예드
마하데오 바스카르 트라이암베이크
체탄 산자이 파와르
가네쉬 나빈찬드라 고트
산지브 아난트 쿨카르니
벤카타 피. 팔레
라젠더 쿠마르 캄보즈
Original Assignee
루핀 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 루핀 리미티드 filed Critical 루핀 리미티드
Publication of KR20140051846A publication Critical patent/KR20140051846A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020137026964A 2011-03-18 2012-03-16 칼슘 감지 수용체 조절자로서의 벤조[ｂ][1,4]옥사진 유도체 Ceased KR20140051846A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN367/KOL/2011 2011-03-18
IN367KO2011 2011-03-18
PCT/IB2012/051268 WO2012127388A1 (en) 2011-03-18 2012-03-16 Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators

Publications (1)

Publication Number Publication Date
KR20140051846A true KR20140051846A (ko) 2014-05-02

Family

ID=54192843

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137026964A Ceased KR20140051846A (ko) 2011-03-18 2012-03-16 칼슘 감지 수용체 조절자로서의 벤조[ｂ][1,4]옥사진 유도체

Country Status (16)

Country Link
US (1) US9464063B2 (OSRAM)
EP (1) EP2686306B1 (OSRAM)
JP (1) JP6033835B2 (OSRAM)
KR (1) KR20140051846A (OSRAM)
CN (1) CN103459377B (OSRAM)
AP (1) AP2013007153A0 (OSRAM)
AU (1) AU2012232706B2 (OSRAM)
BR (1) BR112013023914A2 (OSRAM)
CA (1) CA2829466A1 (OSRAM)
EA (1) EA024893B9 (OSRAM)
IL (1) IL228461A0 (OSRAM)
MX (1) MX2013010670A (OSRAM)
PH (1) PH12013501899A1 (OSRAM)
SG (1) SG193331A1 (OSRAM)
WO (2) WO2012127385A1 (OSRAM)
ZA (1) ZA201306837B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160353592A1 (en) * 2014-11-18 2016-12-01 Shenzhen China Star Optoelectronics Technology Co. A curved display device

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102041154B1 (ko) 2012-02-24 2019-11-07 루핀 리미티드 칼슘 감지 수용체 조절자로서의 치환 크로만 화합물
WO2013136288A1 (en) 2012-03-16 2013-09-19 Lupin Limited Substituted 3,4-dihydro-2h-benzo[b] [1,4]oxazine compounds as calcium sensing receptor modulators
HK1211916A1 (en) * 2012-08-27 2016-06-03 Lupin Atlantis Holdings Sa Arylalkylamine compounds as calcium sensing receptor modulators
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
US9493396B2 (en) 2013-08-28 2016-11-15 Lupin Atlantis Holdings Sa Substituted naphthalene compounds as calcium sensing receptor modulators
EP3060563B1 (en) 2013-10-25 2018-05-02 Novartis AG Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
WO2015162538A1 (en) 2014-04-21 2015-10-29 Lupin Limited Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
PL3200786T3 (pl) 2014-10-03 2020-03-31 Novartis Ag Zastosowanie pochodnych pirydylowych o skondensowanym układzie bicyklicznym jako inhibitorów fgfr4
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
PT3319959T (pt) 2015-07-06 2021-12-06 Alkermes Inc Inibidores hetero-halo de histona desacetilase
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
WO2017037616A1 (en) 2015-08-31 2017-03-09 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
MX394242B (es) 2017-01-11 2025-03-24 Rodin Therapeutics Inc Inhibidores biciclicos de histona desacetilasa
MX2020001484A (es) 2017-08-07 2020-08-20 Rodin Therapeutics Inc Inhibidores bicíclicos de la histona desacetilasa.
BR112022012663A2 (pt) 2019-12-27 2022-09-06 Lupin Ltd Composição farmacêutica de moduladores de casr e métodos e usos da mesma
AU2021207775B2 (en) * 2020-01-17 2025-12-11 Lupin Limited Methods, processes and intermediates for preparing chroman compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1109880A (zh) 1994-02-03 1995-10-11 合成实验室公司 3-(2-氨基乙基)-4-[3-(三氟甲基)苯甲酰基]-3，4-二氢-2h-1，4-苯并噁嗪衍生物、制备及其应用
FR2809396B1 (fr) * 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
US6908935B2 (en) * 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
WO2004069793A2 (en) 2003-01-28 2004-08-19 Bristol-Myers Squibb Company Novel 2-substituted cyclic amines as calcium sensing receptor modulators
CA2527203C (en) 2003-05-28 2010-08-17 Japan Tobacco Inc. Casr antagonist
CA2608194A1 (en) * 2005-05-09 2006-11-16 Hydra Biosciences, Inc. Compounds for modulating trpv3 function
PL1882684T3 (pl) * 2005-05-19 2015-08-31 Astellas Pharma Inc Pochodna pirolidyny albo jej sól
CN101547922B (zh) 2006-10-04 2012-06-20 辉瑞产品公司 作为钙受体拮抗剂的吡啶并[4,3-d]嘧啶-4(3H)-酮衍生物
AU2007318092B2 (en) * 2006-10-26 2013-01-10 Amgen Inc. Calcium receptor modulating agents
EP2085383A4 (en) 2006-11-16 2010-09-22 Astellas Pharma Inc Piperidin derivatives or salts thereof
BRPI0819799A2 (pt) 2007-11-23 2015-05-26 Leo Pharma As Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
WO2010038895A1 (ja) 2008-10-03 2010-04-08 味の素株式会社 ＣａＳＲアゴニスト
WO2010042642A1 (en) 2008-10-08 2010-04-15 Amgen Inc. Calcium receptor modulating agents
WO2010090069A1 (ja) * 2009-02-05 2010-08-12 ヤンマー株式会社 Ｅｇｒ装置及びこれを備えたエンジン装置
CA2762137A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010150837A1 (ja) 2009-06-25 2010-12-29 第一三共株式会社 インドリン誘導体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160353592A1 (en) * 2014-11-18 2016-12-01 Shenzhen China Star Optoelectronics Technology Co. A curved display device
US9763346B2 (en) * 2014-11-18 2017-09-12 Shenzhen China Star Optoelectronics Technology Co., Ltd Curved display device

Also Published As

Publication number Publication date
US9464063B2 (en) 2016-10-11
BR112013023914A2 (pt) 2016-12-13
WO2012127388A1 (en) 2012-09-27
AU2012232706B2 (en) 2016-12-15
SG193331A1 (en) 2013-10-30
CN103459377A (zh) 2013-12-18
IL228461A0 (en) 2013-12-31
EA024893B9 (ru) 2017-01-30
AP2013007153A0 (en) 2013-09-30
MX2013010670A (es) 2013-12-06
CN103459377B (zh) 2016-09-07
ZA201306837B (en) 2015-05-27
US20140018358A1 (en) 2014-01-16
NZ616676A (en) 2015-09-25
CA2829466A1 (en) 2012-09-27
JP2014510097A (ja) 2014-04-24
WO2012127385A1 (en) 2012-09-27
PH12013501899A1 (en) 2013-11-25
EA201370205A1 (ru) 2014-01-30
EP2686306A1 (en) 2014-01-22
EA024893B1 (ru) 2016-10-31
EP2686306B1 (en) 2017-01-04
AU2012232706A1 (en) 2013-09-26
JP6033835B2 (ja) 2016-11-30

Similar Documents

Publication Publication Date Title
KR20140051846A (ko) 칼슘 감지 수용체 조절자로서의 벤조[ｂ][1,4]옥사진 유도체
CN111138301B (zh) 联苯类化合物、其中间体、制备方法、药物组合物及应用
EP2683697B1 (en) Substituted morpholines as modulators for the calcium sensing receptor
JP6994496B2 (ja) 芳香族アセチレンまたは芳香族エチレン系化合物、その中間体、製造方法、薬物組成物および使用
KR102041154B1 (ko) 칼슘 감지 수용체 조절자로서의 치환 크로만 화합물
WO2015162538A1 (en) Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
CA3201608A1 (en) Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof
WO2013136288A1 (en) Substituted 3,4-dihydro-2h-benzo[b] [1,4]oxazine compounds as calcium sensing receptor modulators
WO2014033604A1 (en) Arylalkylamine compounds as calcium sensing receptor modulators
US9493396B2 (en) Substituted naphthalene compounds as calcium sensing receptor modulators
HK1192544A (en) Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators
HK1192544B (en) Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators
WO2015134038A1 (en) Bicyclic pyrrole derivatives useful as agonists of gpr120
NZ616676B2 (en) Benzo [b] [1,4] oxazin derivatives as calcium sensing receptor modulators
OA16592A (en) Benzo [B][1,4] oxazin derivatives as calcium sensing receptor modulators.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131011

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20161115

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170124

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180402

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180801

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180402

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I